Addiction Toxicology Resources
This page has been created by the ACMT Addiction Toxicology Committee and contains pertinent resources with this focus. If you are an ACMT Member interested in joining this Committee please fill out this request form.
Quick Links
Journal of Medical Toxicology Articles
2023
Correction to: The Potential Proconvulsant Effects of Cannabis: a Scoping Review
Authors: Eric E. Kaczor, Kevin Greene, Jennifer Zacharia.
Delta-8-Tetrahydrocannabinol Exposure and Confirmation in Four Pediatric Patients
Delta-8-tetrahydrocannabinol (THC) is a known isomer of delta-9-THC, both found naturally in the Cannabis sativa plant and thought to have similar potency. Authors: Kerollos Shaker, Andrea Nillas, Ross Ellison.
To characterize and compare opioid-only, cocaine-only, methamphetamine-only, opioid-and-cocaine exposure, and opioid-and-methamphetamine exposure and to examine clinical … Authors: Emily Glidden, Kyle Suen, Desiree Mustaquim.
2022
Currently, few hospitals provide medications for opioid use disorder (MOUD) to admitted patients with opioid use disorder (OUD). Authors: Skyler H. Kessler, Evan S. Schwarz, David B. Liss
Phenobarbital has been successfully used in the emergency department (ED) to manage symptoms of alcohol withdrawal, but few studies have reported outcomes for ED patients who receive phenobarbital and … Authors: Jacob A. Lebin, Anita Mudan, Charles E. Murphy IV
The Potential Proconvulsant Effects of Cannabis: a Scoping Review
A total of 3104 unique articles were screened, of which 68 underwent full-text review, and 13 met inclusion/exclusion criteria. Ten of 11 studies evaluating acute cannabis exposures reported a higher seizure inci… Authors: Eric E. Kaczor, Kevin Greene, Jennifer Zacharia
Despite the evidence in support of the use of buprenorphine in the treatment of OUD and increasing ability of emergency medicine (EM) clinicians to prescribe it, emergency department (ED)-initiated buprenorphine… Authors: Utsha G. Khatri, Kathleen Lee, Theodore Lin.
Phenobarbital is frequently used to manage severe alcohol withdrawal. The purpose of this study was to compare the incidence of mechanical ventilation in patients with benzodiazepine-resistant alcohol withdraw… Authors: Poorvi Shah, Kati L. Stegner-Smith, Mohamad Rachid.
Currently, few hospitals provide medications for opioid use disorder (MOUD) to admitted patients with opioid use disorder (OUD). Data are needed to inform… Authors: Skyler H. Kessler, Evan S. Schwarz, David B. Liss.
Lebin, J.A., Mudan, A., Murphy, C.E. et al. Return Encounters in Emergency Department Patients Treated with Phenobarbital Versus Benzodiazepines for Alcohol Withdrawal. J. Med. Toxicol.18, 4–10 (2022). https://doi.org/10.1007/s13181-021-00863-2
2021
Prescription drug monitoring programs (PDMPs) exist in 49 states to guide opioid prescribing. In 40 states, clinicians must check the PDMP prior to prescribing an opioid. Authors: C. James Watson, Michael Ganetsky, Ryan C. Burke.
Buprenorphine is a unique μ-opioid receptor partial agonist with avid receptor binding, nominal euphoric reward, and a ceiling effect on sedation and respiratory depression. Authors: Rachel S. Wightman, Jeanmarie Perrone, Rachel Scagos.
During the current global COVID-19 pandemic and opioid epidemic, wastewater-based epidemiology (WBE) has emerged as a powerful tool for monitoring public health trends by analysis of biomarkers including drugs. Authors: Timothy B. Erickson, Noriko Endo, Claire Duvallet.
Opioid Use and Driving Performance
The USA is in an opioid epidemic, with an increased number of individuals taking psychoactive drugs while executing the tasks of everyday life, including operating a motor vehicle. Authors: Keaton T. Cameron-Burr, Albert Conicella, Mark J. Neavyn.
Methamphetamine toxicity is common in the Southwest region of the United States and presents diagnostic and treatment challenges in the pediatric population. Authors: Hannah R. Malashock, Claudia Yeung, Alexa R. Roberts.
Implementing a hospital medication for addiction treatment (MAT) and a linkage program. Authors: Gillian A. Beauchamp, Lexis T. Laubach.
Medical toxicology expertise has expanded into the addiction medicine realm including outpatient medication for opioid use disorder (MOUD) and addiction treatment. Authors: Shawn M. Varney, Timothy J. Wiegand, Paul M. Wax.
In response to the opioid epidemic, California state officials sought to fund a variety of projects aimed at reducing opioid-related deaths. We describe the California Poison Control System’s (CPCS) successful. Authors: Kathy T. LeSaint, Raymond Y. Ho, Stuart E. Heard.
2020
One hundred and thirty-one out of 382 eligible individuals from at least 76 institutions responded to the survey. A majority (60%) had a DATA 2000 X-waiver, 21% were board-certified in addiction medicine (AM), an… Authors: Joseph E. Carpenter, Brian Patrick Murray.
Mozeika, A.M., Ruck, B.E., Nelson, L.S. et al. Opioid-Associated Hearing Loss: A 20-Year Review from the New Jersey Poison Center. J. Med. Toxicol. 16, 416–422 (2020). https://doi.org/10.1007/s13181-020-00785-5
Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl
Illicitly manufactured fentanyl (IMF) is responsible for a growing number of deaths. Some case series have suggested that IMF overdoses require significantly higher naloxone doses than heroin overdoses. Authors: Joseph Carpenter, Brian Patrick Murray, Sukhshant Atti.
The height of the opioid epidemic in the USA has led to an increasing call for access to medication assisted treatment for opioid use disorder, including buprenorphine initiation from the emergency department … Authors: Megan Chenworth, Jeanmarie Perrone, Jennifer S. Love.
Wastewater-based epidemiology with smart sewer selection and robotic wastewater collection is feasible to detect the presence of specific opioids, naloxone, methadone, and buprenorphine within a city. Authors: Norkio Endo, Newsha Ghaeli, Claire Duvallet, Katelyn Foppe.
Emergency department (ED)–based naloxone distribution programs are a widespread harm reduction strategy. However, data describing the community penetrance of naloxone distributed from these programs are lacking… Authors: Jeffrey T. Lai, Brittany P. Chapman, Stephanie P. Carreiro.
Assessment of the Utility of the Oral Fluid and Plasma Proteomes for Hydrocodone Exposure
Non-medical use and abuse of prescription opioids is a growing problem in both the civilian and military communities, with minimal technologies for detecting hydrocodone use. This study explored the proteomic … Authors: Brooke L. Deatherage Kaiser, Jon M. Jacobs.
3-Hydroxyphencyclidine (3-HO-PCP) is a new psychoactive substance (NPS) and a hydroxy derivative of phencyclidine (PCP), and N-ethylhexedrone (Hexen) is a synthetic cathinone. Authors: Lisa Christine Dunlop, David Wood, John Archer.
Kratom is derived from the plant Mitragyna speciosa…which is indigenous to Southeast Asia. Active compounds, mitragynine and 7-hydroxymitragynine, cause mild stimulant and opioid agonist effects. Authors: Nicholas Nacca, Rachel F. Schult, Lingyun Li.
Electronic cigarettes (e-cigarettes) are battery-operated devices to insufflate nicotine or other psychoactive e-liquid aerosols. Despite initial claims of e-cigarettes as a nicotine-cessation device, aggressive Authors: Dazhe James Cao, Kim Aldy, Stephanie Hsu, Molly McGetrick.
Search the ACMT Learning Center for the Latest Addiction Toxicology Content
Access all of ACMT’s Addiction Toxicology related digital content including webinars, podcasts, and courses on the ACMT Learning Center. Once there, log in to your account or create a FREE one. Then either manually search the site and select Addition Toxicology as your category or click on “Addiction Toxicology” under Search By Topic.
ACMT Webinars
* Denotes webinars accessible only to ACMT Members
Addiction Toxicology Case Conference
The ACMT/ASAM Addiction Toxicology Case Conference is a monthly webinar series that discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology. This activity is free and open to the public.
National Case Conference *
National Journal Club *
2023
March 2023
This month’s topic is Body Stuffers and Naltrexone. The articles will be reviewed by the UCSF Medical Toxicology Fellowship Program, led by Dr. Zhanna Livshits.
2022
July 2021
This month’s topic is Pepper Spray and Tear Gas Agents. The articles will be reviewed by the University of Virginia Program in Medical Toxicology, led by Program Director Heather Borek.
March 2022
This month’s topic is Opioid Overdose and Naltrexone. The articles will be reviewed by the Washington University School of Medicine Program in Medical Toxicology, led by Dr. Evan Schwarz.
2021
May 2021
This month’s topic is Withdrawal and Recent Modalities. The articles will be reviewed by the Rutgers Medical Toxicology Program, led by Dr. Jeena Jaco.
National Grand Rounds *
2022
October 2022
Cannabis Regulation
February 2022
Gone to Pot? The Complex Relationship between Cannabis, Cannabinoids, and Psychosis
2021
October 2021
NPS Discovery – a five-phase approach to NPS identification, characterization, education, and harm reduction
Position Statements and Public Policy Letters
Practice Statements
2021
Sept. Interpretation of Urine Opiate and Opioid Tests. Read statement.
2020
May. Limiting Harms of Vaping and E-cigarette Use. Read statement.
2019
Nov. Interpretation of Urine for Tetrahydrocannabinol Metabolites. Read statement.
Sept. Buprenorphine Administration in the Emergency Department. Read statement.
Apr. Addressing Pediatric Cannabis Exposure. Read statement.
2016
Feb. Safety Issues Regarding Prescription Fentanyl Products. Read statement.
Position Statements
2023
Role of Medical Toxicologist in the Management of Patients with Substance Use Disorder.
2022
ACMT Position Statement: Allow Optimal Treatment for Healthcare Professionals with Opioid Use Disorder
Ryan T. Marino, Meghan Spyres, Timothy J. Wiegand… in Journal of Medical Toxicology (2022)
Stolbach, A., Connors, N., Nelson, L. et al. ACMT Position Statement: Interpretation of Urine Opiate and Opioid Tests. J. Med. Toxicol. 18, 176–179 (2022). https://doi.org/10.1007/s13181-021-00864-1
2021
ACMT Position Statement: Limiting Harms of Vaping and E-cigarette Use
Maryann Mazer-Amirshahi, Fiona M. Garlich… in Journal of Medical Toxicology (2021)
2020
ACMT Position Statement: Caring for Patients with Opioid Use Disorder during Coronavirus Disease Pandemic
Andrew Stolbach, Maryann Mazer-Amirshahi, Evan S. Schwarz… in Journal of Medical Toxicology (2020)
Public Policy Letters
2022
Oct 13, 2022. CSOO Requests DEA and SAMHSA Grant Continued Telehealth Flexibilities for Buprenorphine for OUD Declared in Response to the Opioid PHE. Read letter.
May 13, 2022. The Mainstreaming Addiction Treatment Act. Read letter.
Apr 12, 2022. CSOO Members on FY23 Appropriations Letter Aimed at Strengthening the Addiction Service Workforce. Read letter.
Mar 31, 2022. CSOO Members Support Legislation to Screen, Assess, and Treat Maternal Mental Health Conditions and SUDs. Read letter.
Feb 14, 2022. CSOO Members Advocate the Federal Parity Act be Fully Extended to Medicare, Medicaid, and TRICARE. Read letter.
2021
Jul 26, 2021. CSOO Urges Biden Administration to Fly Flags at Half-Staff on Overdose Awareness Day. Read letter.
May 27, 2021. Introduction of the Support, Treatment, and Overdose Prevention of (S.T.O.P) Fentanyl Act of 2021. Read letter.
May 3, 2021. Excellence in Recovery Housing Act. Read letter.
April 6, 2021. CSOO Urges Congress to Include Funding for Programs to Strengthen the Addiction Service Workforce in Fiscal Year 2022. Read letter.
2020
May 5, 2020. CSOO Urges Congress to Include Key Initiatives to Support the Mental Health and SUD Treatment Infrastructure in Next COVID-19 Package. Read letter.
ACMT Visual Pearls
I’ll Huff and I’ll Puff…
Jun 22, 2020 | ACMT Visual Pearls, Tox & Medications
By: Kathryn T. Kopec, DO and Blake Bauer, MD
“I have a nagging feeling about this”
Oct 5, 2020 | ACMT Visual Pearls, Emergency Medicine, Tox & Medications
By: Brian Lewis, MD, Gilbert Nelson, DO, Thomas Vu, DO and Bryan Judge, MD, FACMT
Case of a Toxic Tea
Nov 9, 2020 | ACMT Visual Pearls, Emergency Medicine, Tox & MedicationsBy: Nicholas Titelbaum, MD, Vir Singh, MD and Daniel Nogee, MD
ACMT Highlights Tox-in-Ten
Episode 45: Pregnancy and Methamphetamine
Dr. Gillian Beauchamp sits down with Dr. Tricia Wright to discuss risk factors leading to methamphetamine use disorder, associated complications in pregnancy, and management of substance use disorder in pregnant and postpartum patients.
Episode 44: Cannabis Use in Pregnancy
Dr. Gillian Beauchamp sits down with Dr. Tricia Wright to discuss the known and theoretical risks of cannabis use during pregnancy and lactation.
Episode 43: Substance Use, Pregnancy, and Stigma
Dr. Gillian Beauchamp sits down with Dr. Mishka Terplan to discuss discrimination and prejudice in relation to substance use in pregnancy.
Episode 42: Neonatal Abstinence Syndrome
Dr. Gillian Beauchamp sits down with Dr. Lori Devlin to discuss Neonatal Abstinence Syndrome (NAS), Neonatal Opioid Withdrawal Syndrome (NOWS), and the treatment of NOWS.
Episode 41: Physical Dependence vs. Addiction vs. Substance Use Disorder
Dr. Gillian Beauchamp sits down with Dr. Kurt Kleinschmidt to discuss the differences between dependence, addiction, and substance use disorder and how it relates to medication associated treatment (MAT).
Episode 40: Does Science Support the DRE Assessment
Dr. Gillian Beuachamp sits down with Assistant Chief of Police Matthew Myers to discuss the Drug Recognition Evaluation (DRE) and the Drug Influence Evaluation (DRE) assessments.
Episode 28: Methamphetamine in Children
Dr. Gillian Beauchamp sits down with Dr. Ayrn O’Connor to discuss the clinical presentation and treatment of methamphetamine toxicity in children.
Episode 27: Neural Network Connectivity and Methamphetamine
Dr. Gillian Beauchamp sits down with Dr. Milky Kohno, PhD to discuss naltrexone as a treatment strategy for methamphetamine use disorder.
Episode 26: Harm Reduction Strategies
Dr. Gillian Beauchamp sits down with Shaun Hopkins to discuss syringe services programs (SSPs) and overdose prevention sites (OPS).
Episode 24: Complicated Alcohol Withdrawal
Dr. Gillian Beauchamp sits down with Dr. Michael Lynch to discuss refractory ethanol withdrawal and the role of ketamine.
Episode 22: Chronic Effects on the Heart by Methamphetamine and Other Stimulants
Dr. Gillian Beauchamp Sits down with Dr. Stephanie Weiss to discuss the chronic effects of methamphetamine and other stimulants such as cocaine on the heart.
Episode 11: The Great US Cannabis Experiment
Dr. Gillian Beauchamp sits down with Dr. Marilyn Huestis to recap her talk The Great US Cannabis Experiment: Short and Long Term Consequences.
Episode 9: Acute Opioid Toxicity: Naloxone Gone Wrong
Dr. Gillian Beauchamp sits down with Emergency Medicine Physician and Medical Toxicologist Dr. Lewis Nelson to discuss dosing, use and potential pitfalls of naloxone for acute opioid overdose.
Episode 8: Buprenorphine
Dr. Gillian Beauchamp sits down with Emergency Medicine Physician and Dr. Timothy Wiegand for a discussion of the history, benefits and potential complications of buprenorphine therapy for opioid use disorder.
Episode 7: Death by Methadone
Dr. Gillian Beauchamp sits down with Emergency Medicine Physician and Medical Toxicologist Dr. Timothy Wiegand for a discussion on the history of methadone and it’s potential toxicity.
Episode 6: Dead Men Do Tell Tales
Dr. Gillian Beauchamp sits down with Chief Medical Examiner of Connecticut, Dr. James Gill. Listen to their discussion about opioid related deaths.
Episode 5: The Opioid Epidemic and How We Got Here
Dr. Gillian Beauchamp sits down with Emergency Medicine Physician and Medical Toxicologist Dr. Jeanmarie Perrone at the Seminar in Forensic Toxicology.